Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
27.5M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
8.28M
-
Shares change
-
-8.23K
-
Total reported value, excl. options
-
$10.5M
-
Value change
-
+$7.41K
-
Number of buys
-
9
-
Number of sells
-
-13
-
Price
-
$1.27
Significant Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q3 2025
38 filings reported holding ANTX - AN2 Therapeutics, Inc. - Common Stock and Warrants as of Q3 2025.
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.28M shares
of 27.5M outstanding shares and own 30.13% of the company stock.
Largest 10 shareholders include Almitas Capital LLC (1.43M shares), VANGUARD GROUP INC (1.08M shares), Pfizer Inc (715K shares), Peapod Lane Capital LLC (589K shares), Stonepine Capital Management, LLC (564K shares), BANK OF NOVA SCOTIA (459K shares), LANDSCAPE CAPITAL MANAGEMENT, L.L.C. (456K shares), BANK OF MONTREAL /CAN/ (422K shares), RENAISSANCE TECHNOLOGIES LLC (386K shares), and BANK OF AMERICA CORP /DE/ (385K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.